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Fungal peritonitis is a serious complication of peritoneal
dialysis but previous reports on this have been limited to
small, single-center studies. Using all Australian peritoneal
dialysis patients, we measured predictors, treatments, and
outcomes of this condition by logistic regression and
multilevel, multivariate Poisson regression. This
encompassed 66 centers over a 4-year period that included
162 episodes of fungal peritonitis (4.5% of all peritonitis
episodes) that occurred in 158 individuals. Candida albicans
(25%) and other Candida species (44%) were the most
common fungi isolated. Fungal peritonitis was independently
predicted by indigenous race and prior treatment of bacterial
peritonitis. Peritonitis episodes occurring after 7 and 60 days
of treatment for previous bacterial peritonitis decreases in
the probability of fungal peritonitis 23 and 6%, respectively.
Compared with other organisms, fungal peritonitis was
associated with significantly higher rates of hospitalization,
catheter removal, transfer to permanent hemodialysis, and
death. The risks of repeat fungal peritonitis and death were
lowest with catheter removal combined with antifungal
therapy when compared to either intervention alone. Our
study shows that fungal peritonitis is a serious complication
of peritoneal dialysis and should be strongly suspected in the
context of recent antibiotic treatment for bacterial peritonitis.
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Fungal peritonitis is a serious complication of peritoneal
dialysis (PD). It is reported to be caused by yeast (Candida
species) in at least 75% of cases, account for between 1% and
15% of all PD-associated peritonitis episodes, respond
variably to treatment and result in high rates of both
technique failure (X40%) and death (5–53%).1–4 The 2005
update of the International Society of PD (ISPD) Guidelines
for Management of PD-related Infections recommends
immediate catheter removal after fungi are identified by
microscopy or culture, followed by continuation of anti-
fungal therapy for an additional 10 days.5 However, these
recommendations are based on the limited observations
involving relatively small case series (5–70 cases) from the
1980s and 1990s involving single centers (often where PD
expertise is concentrated).1–4,6–15 Moreover, there has not
been a comprehensive examination of different therapeutic
approaches to fungal peritonitis within each of these centers.
The aim of this study was to examine the frequency, pre-
dictors, treatment and clinical outcomes of fungal peritonitis
in all Australian PD patients involving 66 PD centers.
RESULTS
Population characteristics
A total of 4675 patients received PD in Australia during the
study period (1 October 2003 to 31 December 2006). They
were followed for 6002 patient-years. One hundred and sixty-
two episodes of fungal peritonitis occurred in 158 indivi-
duals. Fungi accounted for 4.5% of all peritonitis episodes.
The rates of all peritonitis and fungal peritonitis were 0.60
and 0.03 episodes per patient-year of treatment, respectively.
The organisms isolated in cases of fungal peritonitis included
Candida albicans (n¼ 41), other Candida species (n¼ 72),
and other fungi (n¼ 52). In two cases, C. albicans was
isolated together with another Candida species. Additional
non-fungal organisms were isolated in 35 (22%) episodes of
fungal peritonitis, including coagulase-negative staphylococci
(n¼ 10), S. aureus (n¼ 5), streptococci (n¼ 3), enterococci
(n¼ 5), other Gram-positive organisms (n¼ 1), Pseudomo-
nas (n¼ 2), Acinetobacter (n¼ 2), Escherichia coli (n¼ 5),
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Klebsiella (n¼ 6), Enterobacter (n¼ 5), other Gram-negative
organisms (n¼ 4), and anaerobic bacteria (n¼ 1).
Predictors of fungal peritonitis
The characteristics of patients who did and did not experience
fungal peritonitis are shown in Table 1. On univariate analysis,
patients who experienced fungal peritonitis during the study
period were more likely to be Aboriginal and Torres Strait
Islander peoples, living in Western Australia or Northern
Territory, and tended to be less likely to have missing baseline
peritoneal equilibration test data than those individuals who
did not experience fungal peritonitis.
The hierarchical multivariate poisson model showed that
fungal peritonitis incidence was significantly and indepen-
dently predicted by Aboriginal/Torres Strait Islander racial
origin (adjusted incidence rate ratio (IRR) 1.94, 95%
Table 1 | Characteristics of all Australian PD patients who did or did not experience fungal peritonitis at any stage during the
period 2003–2006
Characteristic Fungal peritonitis (n=158) No fungal peritonitis (n=4517) P-value
Age (years) 62.7±16.5 61.5±16.7 0.4
Women 73 (46%) 2053 (45%) 0.9
Racial origin 0.001
Caucasian 109 (69%) 3471 (77%)
Aboriginal/Torres Strait Islander 27 (17%) 361 (8%)
Maori/Pacific Islander 5 (3%) 76 (2%)
Asian 13 (8%) 428 (9%)
Other 4 (3%) 180 (4%)
BMI (kg/m2) 26.0±5.0 26.0±6.1 1.0
eGFR at dialysis start (ml/min per 1.73m2) 6.7±6.4 7.1±4.4 0.4
Late referral 43 (27%) 1068 (24%) 0.6
ESRF cause 0.4
Chronic glomerulonephritis 44 (28%) 1279 (28%)
Diabetic nephropathy 52 (33%) 1267 (28%)
Renovascular disease 22 (14%) 617 (14%)
Polycystic kidneys 3 (2%) 253 (6%)
Reflux nephropathy 8 (5%) 189 (4%)
Other 21 (13%) 624 (14%)
Unknown 8 (5%) 288 (6%)
Current smoker 26 (16%) 754 (17%) 0.16
Chronic lung disease 19 (12%) 580 (13%) 0.8
Coronary artery disease 66 (42%) 1601 (35%) 0.3
Peripheral vascular disease 32 (20%) 1014 (22%) 0.8
Cerebrovascular disease 22 (14%) 586 (13%) 0.9
Diabetes mellitus 63 (40%) 1675 (37%) 0.5
HIV positive 0 (0%) 6 (0.1%) 0.6
Previous failed kidney transplant 6 (4%) 206 (5%) 0.8
Peritoneal transport status 0.10
High 17 (11%) 454 (10%)
High average 63 (40%) 1648 (36%)
Low average 41 (26%) 1037 (23%)
Low 10 (6%) 188 (4%)
Unknown/not specified 27 (17%) 1190 (26%)
Center size (no. PD patients) 0.9
Small (p10) 2 (1%) 53 (1%)
Small–medium (11–38) 13 (8%) 308 (7%)
Medium–large (39–98) 35 (22%) 993 (22%)
Large (X99) 108 (68%) 3163 (70%)
State o0.001
New South Wales 54 (34%) 1778 (39%)
Northern Territory 13 (8%) 72 (2%)
Queensland 26 (16%) 929 (21%)
South Australia 5 (3%) 290 (6%)
Tasmania 0 (0%) 77 (2%)
Victoria 34 (22%) 926 (21%)
Western Australia 26 (16%) 445 (10%)
BMI, body mass index; eGFR, epidermal growth factor receptor; ESRF, end-stage renal failure; PD, peritoneal dialysis.
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confidence interval (CI) 1.15–3.28). There were also trends
toward a lower incidence in patients with a diagnosis of
polycystic kidney disease compared with other causes of
ESKD (IRR 0.36, 95% CI 0.11–1.18, P¼ 0.09) and with a
higher estimated glomerular filtration rate (eGFR) at the time
of commencement of dialysis (IRR for highest quartile 0.64,
95% CI 0.38–1.06, P¼ 0.09). The development of fungal
peritonitis was not associated with age, gender, body mass
index, chronic lung disease, coronary artery disease, current
smoking at renal replacement therapy start, peripheral
vascular disease, cerebrovascular disease, diabetes mellitus,
or late referral within 3 months of needing to start dialysis.
Effect of previous peritonitis episodes and antifungal
prophylaxis
A history of previous peritonitis was equally likely for any
given episode of fungal peritonitis episode as for a non-
fungal peritonitis episode (43 vs 45%, respectively, P¼ 0.3).
However, the time elapsed between an earlier peritonitis
episode and the subsequent one was shorter for fungal
peritonitis (median period 53 days, interquartile range (IQR)
20–131 days) than for non-fungal peritonitis (median 79
days, IQR 36–186 days, P¼ 0.002), such that the probability
of an episode of peritonitis being caused by a fungus
progressively increased as the time elapsed since an earlier
peritonitis episode decreased (Figure 1). Specifically, if a
peritonitis episode occurred within 7, 15, 30, or 60 days of
completion of treatment for an earlier peritonitis episode, the
respective probabilities of the current peritonitis episode
being caused by a fungus were 23, 13, 7, and 6%. The
corresponding odds ratios for fungal peritonitis were 7.00
(95% CI 2.51–19.6), 3.75 (95% CI 1.93–7.26), 2.16 (95% CI
1.30–3.60), and 1.68 (95% CI 1.04–2.73). No difference was
observed in the time elapsed between an earlier peritonitis
episode and subsequent fungal peritonitis due to Candida
species (median 53 days, IQR 14–121.5 days) versus other
fungal organisms (median 53 days, IQR 21–159 days, P¼ 0.6).
Moreover, the occurrence of culture-negative peritonitis
before a fungal peritonitis episode was not significantly
different from the occurrence of culture-negative peritonitis
in the total population (16 vs 12%, respectively, P¼ 0.4).
Only 260 (7%) patients were co-prescribed antifungal
prophylaxis during any given peritonitis episode. In patients
experiencing more than one peritonitis episode, the occur-
rence of fungal peritonitis was comparable between those
who did and did not receive antifungal prophylaxis during
earlier peritonitis episodes (4 vs 5%, respectively, P¼ 0.8).
Treatment of fungal peritonitis
The vast majority of patients with fungal peritonitis were
initially treated with either intraperitoneal vancomycin or
cephazolin in combination with gentamicin as empiric
therapy (Table 2). Antifungal chemotherapy was adminis-
tered in the initial empiric regimen in 33 (20%) episodes.
Ultimately, 105 (65%) fungal peritonitis episodes were
treated with antifungal agents, either alone (11 or 7%) or
in conjunction with catheter removal (94 or 58%). Forty-
eight (30%) fungal peritonitis episodes were treated with
catheter removal alone, whereas 9 (6%) patients died before
receiving either antifungal agents or catheter removal. The
most commonly administered antifungal regimen in the
initial, second, or third antimicrobial treatment courses was
fluconazole monotherapy (90%), followed by amphotericin B
monotherapy (20%), fluconazole and flucytosine (3%),
amphotericin and fluconazole (2%), and ketaconazole
(1%). Of the 13 episodes of fungal peritonitis initially treated
with amphotericin monotherapy, treatment was changed to
fluconazole monotherapy in four (31%) cases. Of the 91
episodes of fungal peritonitis initially treated with flucona-
zole monotherapy, treatment was changed to amphotericin
monotherapy in seven (8%) cases, combination of ampho-
tericin and fluconazole in two (2%) cases, and combination
of fluconazole and flucytosine in three (3%) cases. Overall,
the median total antifungal course duration was 15 days
(Table 3). Heparin was administered to dialysate in 35 (22%)
episodes of fungal peritonitis. Streptokinase was instilled in
the PD catheter in one (1%) episode of fungal peritonitis.
The approach to treatment of fungal infections did not
appreciably vary between Australian states.
Outcomes of fungal peritonitis
Fungal peritonitis episodes frequently resulted in hospitaliza-
tion (98%), catheter removal (88%), permanent hemodialysis
transfer (74%), and death (9%) (Table 3). Compared with
non-fungal peritonitis, fungal peritonitis was associated with
significantly greater frequencies of occurrence of these
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Figure 1 |Occurrence of fungal and non-fungal peritonitis
following previous peritonitis. Histograms demonstrating the
temporal occurrence of (a) fungal peritonitis and (b) non-fungal
peritonitis in relation to an earlier episode of treated non-fungal
peritonitis in Australian peritoneal dialysis patients who had
experienced more than one episode of peritonitis during the
study period.
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outcomes, as well as a longer duration of hospitalization and
shorter time to catheter removal (Table 3). The frequencies of
hospitalization, catheter removal, permanent hemodialysis
transfer, and death were comparable between peritonitis
episodes in which a fungus only was isolated or those in
which multiple organisms (including a fungus) were isolated
(98 vs 100%, 87 vs 89%, 71 vs 81%, and 8 vs 9%,
respectively).
Nine (6%) patients died before receiving treatment with
either antifungal therapy or catheter removal. The risk of
death was higher with antifungal treatment alone (18%) than
with either catheter removal alone (6%) or catheter removal
plus antifungal treatment (7%), although the differences did
not reach statistical significance due to the relatively small
numbers of deaths in each group (2, 3, and 7, respectively).
The risk of a subsequent repeat fungal peritonitis episode was
Table 2 | Antimicrobial agents prescribed in initial, second, and third antibiotic regimens for fungal peritonitis episodes in
Australian peritoneal dialysis patients 2003–2006
Antibiotic First regimen (n=162) Second regimen (n=108) Third regimen (n=39)
Amphotericin 4 (2%) 12 (11%) 5 (13%)
Fluconazole 28 (17%) 50 (46%) 17 (44%)
Flucytosine 0 (0%) 1 (1%) 2 (5%)
Ketoconazole 1 (1%) 0 (0%) 0 (0%)
Cephazolin 49 (30%) 8 (7%) 3 (8%)
Vancomycin 76 (47%) 18 (17%) 7 (18%)
Gentamicin 84 (52%) 9 (8%) 4 (10%)
Other aminoglycoside 2 (1%) 0 (0%) 0 (0%)
Other cephalosporin 39 (24%) 16 (15%) 5 (13%)
Ciprofloxacin 6 (4%) 5 (5%) 4 (10%)
b-Lactam 8 (5%) 8 (7%) 2 (5%)
Teicoplanin 1 (1%) 0 (0%) 0 (0%)
Imipenem 1 (1%) 0 (0%) 0 (%)
Rifampicin 1 (1%) 0 (0%) 0 (0%)
Metronidazole 4 (2%) 7 (6%) 4 (10%)
Other 7 (4%) 14 (13%) 7 (18%)
Results represent number of episodes treated with antibiotic (% of total treated with first-, second-, or third-line regimen). Note that values within each column add to more
than 100% because of the use of combination antimicrobial regimens.
Table 3 | Treatment characteristics and clinical outcomes of peritoneal dialysis-associated peritonitis because of fungi or other
organisms in Australia 2003–2006
Outcome Fungal peritonitis (n=162 episodes) Non-fungal peritonitis (n=3432 episodes) P-value
Treatment
Change to second antibiotic regimen 108 (67%) 1902 (55%) 0.006
Time to second antibiotic regimen 3 [1–6] 3 [2–5] 0.8
Change to third antibiotic regimen 39 (24%) 458 (13%) o0.001
Time to third antibiotic regimen 6 [3.75–15.5] 6 [4–10] 0.5
Total antibiotic treatment duration 15 [5–26] 14 [8–19] 0.4
Hospitalisation
Number (%) 159 (98%) 2345 (68%) o0.001
Duration (days) 10 [5–24.5] 6 [3–11] o0.001
Catheter removal
Number (%) 142 (88%) 633 (18%) o0.001
Time to occurrence (days) 5 [2–9] 7 [4–14] o0.001
Temporary hemodialysis
Number (%) 20 (12%) 132 (4%) o0.001
Time to occurrence (days) 4 [2–11] 6 [3–12] 0.5
Duration (days) 90 [61–152] 65.5 [21.75–99.25] 0.017
Permanent hemodialysis
Number (%) 120 (74%) 515 (15%) o0.001
Time to occurrence 6 [3–10] 7 [4–13.5] 0.003
Death
Number (%) 14 (9%) 68 (2%) o0.001
Time to death 14 [5–26] 11 [3–22.5] 0.8
Results are expressed as number (%) or median days [interquartile range].
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significantly lower with combined catheter removal and
antifungal therapy (0%) than with antifungal treatment alone
(9%) or catheter removal alone (6%, P¼ 0.03). In patients
who had their catheters removed, the probabilities of
returning to PD following an interim period of hemodialysis
were comparable for fungal peritonitis episodes, which were
or were not treated with concomitant antifungal therapy (15
vs 17%, P¼ 0.8). Tenckhoff catheter removal occurred in 142
(88%) cases of fungal peritonitis after a median period of 5
days. In those patients who had their catheters removed, the
outcomes for early (within 5 days) versus late (45 days)
removal were comparable with respect to permanent
hemodialysis transfer (83 vs 86%, P¼ 0.6) and death (6 vs
8%, P¼ 0.8) (Table 4).
DISCUSSION
This study, involving 162 cases of PD-associated fungal
peritonitis across 66 different PD centers, represents the
largest examination to date of the frequency, predictors,
treatment and clinical outcomes of this important condition.
Fungal peritonitis accounted for 4.5% of all PD-related
peritonitis episodes and was mostly (68%) caused by
Candida species. Importantly, other micro-organisms in
addition to fungi were isolated in 22% of cases. Fungal
peritonitis was predicted by Aboriginal and Torres Strait
Islander racial origin and recent completion of antibiotic
treatment for bacterial peritonitis. Compared with other
types of PD-associated peritonitis, fungal peritonitis was
associated with significantly higher rates of hospitalization
(98 vs 68%), catheter removal (88 vs 18%), permanent
hemodialysis transfer (74 vs 15%), and death (9 vs 2%). In
the context of polymicrobial peritonitis, the presence of
fungus was the principal determinant of clinical outcome.
Catheter removal in combination with antifungal therapy
resulted in the best overall outcome with the lowest rates of
repeat fungal peritonitis episodes and death compared with
either therapeutic intervention on its own. However, no
difference in outcome was observed between those episodes
treated with earlier (within 5 days) rather than later catheter
removal.
The clinical outcomes of fungal peritonitis in Australia
were generally comparable with those of a number of single-
center experiences. Wang et al.14 reported on 70 episodes of
fungal peritonitis at a single center in Hong Kong between
1989 and 1998. Similar to the findings of our study, they
observed that fungal peritonitis accounted for 5.8% of all
peritonitis episodes with 70% of all fungal peritonitis caused
by Candida species. However, compared with our study, they
reported lower rates of catheter removal (83 vs 88%) and
permanent hemodialysis transfer (14.5 vs 74%), but higher
mortality (44 vs 9%). The higher incidence of death from
fungal peritonitis in the Hong Kong experience may have
been attributable to a higher proportion of rare non-Candida
fungal organisms, lower rate of catheter removal, longer time
to median catheter removal (7 days vs 5 days), and lower
rate of permanent hemodialysis transfer. The low rate of
hemodialysis transfer probably reflected the predominant
usage of PD as renal replacement therapy in this country.
Leaving the PD catheter in situ was significantly associated
with increased mortality. Similarly, in a recent single-center
experience from India16 of 43 episodes of fungal peritonitis
between January 1998 and February 2008, catheter removal
occurred in only 58% of cases, with the 1 month mortality
rate being 60%. The subsequent multivariate analysis
demonstrated that the only two significant, independent
predictors of death were a serum albumin concentration less
than 30 g/l and the PD catheter remaining in situ.
More comparable outcomes to those of our paper were
reported in a series of 18 PD-associated fungal peritonitis
episodes in the UK population between December 1999 and
September 2003.17 These fungal peritonitis cases represented
6% of all peritonitis episodes during this period and Candida
species were the infecting organism in 83% of cases. Catheter
removal occurred in 83% of cases, mostly between 2 and 13
days following diagnosis. Mortality in this population was
11% attributed to fungal peritonitis and 6% because of
withdrawal from dialysis from other causes. All surviving
patients were permanently transferred to hemodialysis.
Recent antibiotic treatment for peritonitis (or any other
indication) has consistently been identified as an important
risk factor for fungal peritonitis.2,7,8 In a report of six cases of
fungal peritonitis observed between 1980 and 1992 in an
Italian center, Amici et al.7 observed that all six patients had
suffered at least one episode of treated bacterial peritonitis in
the 2 months before the fungal infection appeared. The
authors subsequently analyzed 22 published reports of fungal
peritonitis and identified that the major predisposing factors
were earlier antibiotic therapy and bacterial peritonitis.
Similarly, Michel et al.2 found that 16 of 20 patients
experienced bacterial peritonitis during the month before
they developed fungal peritonitis. In our study, a history of
earlier treated peritonitis was more than twice as likely with
fungal peritonitis compared with non-fungal peritonitis, and
became even more likely if the elapsed time between episodes
was short. Specifically, 6% of peritonitis episodes occurring
within 2 months of a previous non-fungal peritonitis event
were confirmed to be fungal peritonitis. However, if the
peritonitis occurred within 7 days of completing treatment
for previous peritonitis, approximately one-quarter of such
events were fungal. Clinicians should therefore be highly
Table 4 | Effect of timing of catheter removal on subsequent
clinical outcomes in 142 patients with fungal peritonitis
requiring catheter removal
Number of days from peritonitis
onset to catheter removal
Characteristic
p5 Days
(n=64)
45 Days
(n=78) P-value
Permanent hemodialysis
transfer
67 (86%) 53 (83%) 0.6
Death 6 (8%) 4 (6%) 0.8
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suspicious of fungal peritonitis in patients presenting with
signs and symptoms of peritonitis soon after treatment for
PD-associated peritonitis and, under such circumstances,
strongly consider empiric antifungal therapy. It is also
important to note that 57% of cases of fungal peritonitis in
our study had no earlier history of antibiotic treatment for
bacterial peritonitis.
When fungus is identified by microscopy or culture, the
ISPD guidelines recommend immediate catheter removal and
continuation of antifungal agents for an additional 10 days.
Although these recommendations are based on the reports of
several single-center studies,1,2,12,14,15,18 other single-center
case series have advocated for catheter removal alone
(followed by antifungal therapy if the clinical response is
poor)3 or antifungal therapy alone (followed by catheter
removal if the clinical response is poor).7,8,11 In our large
multicentre study, the risk of death was higher with
antifungal treatment alone (18%) than with either catheter
removal alone (6%) or catheter removal plus antifungal
treatment (7%). Moreover, the risk of a subsequent repeat
fungal peritonitis episode was significantly lower with
combined catheter removal and antifungal therapy (0%)
than with antifungal treatment alone (9%) or catheter
removal alone (6%, P¼ 0.03). These findings support the
current ISPD recommendations,5 although we were unable to
demonstrate a clinical benefit for immediate or early (within
5 days) catheter removal, as opposed to later removal,
provided antifungal therapy had been instituted.
Another noteworthy finding of our study was the relatively
low (7%) use of antifungal prophylaxis during treatment
for bacterial peritonitis in Australia. A previous randomized
controlled trial of oral nystatin 500,000 U q.i.d. whenever
antibiotics were prescribed resulted in a significant
reduction of the risk of superimposed fungal peritonitis
(397 patients, 1168 patient-months, relative risk 0.10, 95% CI
0.03–0.31).19,20 Consequently, the ISPD Guidelines recom-
mend that fungal prophylaxis during antibiotic therapy may
prevent some cases of Candida peritonitis in programs that
have high rates of fungal peritonitis.5 The occurrence of
fungal peritonitis in our study was comparable between those
who did and did not receive antifungal prophylaxis during
earlier peritonitis episodes (4 vs 5%, respectively, P¼ 0.8).
However, these results may have been limited by selection
bias and type 2 statistical error due to limited sample size.
Further randomized controlled trials to address the efficacy
of oral nystatin prophylaxis are warranted.
In addition to recent antibiotic therapy for bacterial
peritonitis, our study also identified Aboriginal/Torres Strait
Islander racial origin as an independent risk factor for fungal
peritonitis. We have previously demonstrated that indigenous
racial origin is associated with a higher risk of peritonitis in
general, which is independent of the increased risks of
diabetes mellitus, obesity, and other co-morbidities in this
group.21 Socioeconomic factors, such as housing conditions,
and remoteness of living are likely to be important
contributors to the increased risk of fungal peritonitis in
this study, as environmental exposures have been found to
predispose to Candida peritoneal infections.22,23 Unfortu-
nately, social disadvantage and remoteness could not be
evaluated in this study because of the limited data collected
by the ANZDATA Registry. Nevertheless, as hospitals serve
areas with differing socioeconomic status, there will have
been some accounting for this effect by the hierarchical
nature of the poisson analysis. Previous studies have
identified a strong association between socioeconomic
disadvantage and end-stage kidney disease among indigenous
Australians.24 On the basis of the residential postcodes, we
have previously demonstrated that Aboriginal PD patients
were more likely to reside in non-metropolitan than
metropolitan areas, but we were unable to adequately
evaluate how remoteness (compared with urban and peri-
urban residences) influenced fungal peritonitis risk in
indigenous patients.21 It is likely, however, that the high
rates of fungal infection observed in Western Australia (6%)
and Northern Territory (15%) compared with other
Australian states (0–3.5%) reflected a high proportion of
indigenous PD patients (Western Australia 22% vs Northern
Territory 77% vs other states 5%), often living in disadvan-
taged circumstances in remote and rural locations.25
The strengths of this study included its very large sample
size, inclusiveness, and robust analyses. We included all
patients receiving PD in Australia across 66 centers during
the study period, such that a variety of centers were included
with varying approaches to the treatment of peritonitis. This
greatly enhanced the external validity of our findings. These
strengths should be balanced against the study’s limitations,
which included limited depth of data collection. ANZDATA
does not collect important information, such as the presence
of concomitant exit site and tunnel infections, patient
compliance, individual unit management protocols, post-
infection surveillance programs, concurrent medications
(such as glucocorticoids), laboratory values (such as
C-reactive protein and dialysate white cell counts), severity
of co-morbidities, antifungal dosages, or routes of antifungal
administration. Even though we adjusted for a large number
of patient characteristics, the possibility of residual con-
founding could not be excluded. In common with other
Registries, ANZDATA is a voluntary Registry and there is no
external audit of data accuracy, including the diagnosis of
peritonitis. Consequently, the possibility of coding/classifica-
tion bias cannot be excluded.
In conclusion, fungal peritonitis is a serious, not
infrequent complication of PD, which is associated with
a high rate of hospitalization (98%), catheter removal
(88%), permanent hemodialysis transfer (74%), and death
(9%). Previous treated bacterial peritonitis (especially if
recent) and indigenous racial origin are major risk factors for
this condition. Catheter removal in combination with
antifungal therapy appears to result in the best overall
outcome with the lowest rates of repeat fungal peritonitis
episodes and death compared with either therapeutic
intervention alone.
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MATERIALS AND METHODS
Study population
The study included all Australian adult patients from the ANZDATA
Registry who were receiving PD between 1 October 2003 (when
detailed peritonitis data started to be collected) and 31 December
2006. The data collected included demographic data, cause of pri-
mary renal disease, co-morbidities at the start of dialysis (coronary
artery disease, peripheral vascular disease, cerebrovascular disease,
chronic lung disease, diabetes, hypertension, and smoking status),
body mass index, late referral (defined as commencement of dialysis
within 3 months of referral to a nephrologists), microbiology of
peritonitis episodes (up to three organisms for polymicrobial
episodes), and the initial and subsequent antibiotic treatment
regimens. The organism responsible for fungal peritonitis was coded
as C. albicans, other Candida species, or other fungus. In cases of
polymicrobial peritonitis, fungal peritonitis was recorded if a fungus
was at least 1 of the isolated organisms. Center size was categorized
according to quartiles: small (o11 patients), small-medium (11–38
patients), medium-large (39–98 patients), and large (499 patients).
The outcomes examined were peritonitis relapse, repeat
peritonitis, peritonitis-associated hospitalization, catheter removal,
temporary or permanent transfer to hemodialysis, and patient
death. Peritonitis recurrence was defined as an episode of peritonitis
occurring within 4 weeks of the last antibiotic dose (or within 5
weeks if intermittent vancomycin used) for peritonitis due to the
same organism. Repeat peritonitis was defined as an episode of
peritonitis occurring more than 4 weeks after the last antibiotic dose
(or more than 5 weeks if intermittent vancomycin used) for
peritonitis due to the same organism.
Statistical analysis
Results were expressed as frequencies and percentages for categorical
variables, mean±s.d. for continuous variables, and median and IQR
for nonparametric data. Differences between two groups of patients
were analyzed by w2-test for categorical data, unpaired t-test for
continuous parametric data, and Mann–Whitney test for continuous
nonparametric data. The independent predictors of fungal perito-
nitis were determined by multivariate poisson regression using
backward stepwise elimination.26 First-order interaction terms
between the significant covariates were examined for all analyses.
To account for the structure of the data, a multi-level hierarchical
model was created with a random effect for state of residence,
treating unit and individual patient. Predictors of peritonitis
outcomes were assessed by multivariable binary logistic regression.
Data were analyzed using the software packages SPSS for Windows
release 12.0 (SPSS Inc., North Sydney, Australia) and Stata/SE 10.1
(College Station, TX). P-values less than 0.05 were considered
statistically significant.
DISCLOSURE
Professor David Johnson is a consultant for Baxter Healthcare Pty Ltd
and has previously received research funds from this company.
He has also received speakers’ honoraria and research grants from
Fresenius Medical Care. Dr Kym Bannister is a consultant for Baxter
Healthcare Pty Ltd. Dr Stephen McDonald has received speaking
honoraria from Fresenius Australia and Baxter Australia. All other
authors declared no competing interests.
ACKNOWLEDGMENTS
We gratefully acknowledge the substantial contributions of the entire
Australia and New Zealand nephrology community (physicians,
surgeons, database managers, nurses, renal operators, and patients)
for providing information for and maintaining the ANZDATA Registry
database.
REFERENCES
1. Prasad N, Gupta A. Fungal peritonitis in peritoneal dialysis patients. Perit
Dial Int 2005; 25: 207–222.
2. Michel C, Courdavault L, al Khayat R et al. Fungal peritonitis in patients on
peritoneal dialysis. Am J Nephrol 1994; 14: 113–120.
3. Nagappan R, Collins JF, Lee WT. Fungal peritonitis in continuous
ambulatory peritoneal dialysis – the Auckland experience. Am J Kidney Dis
1992; 20: 492–496.
4. Lo WK, Chan TM, Lui SL et al. Fungal peritonitis – current status 1998.
Perit Dial Int 1999; 19(Suppl 2): S286–S290.
5. Piraino B, Bailie GR, Bernardini J et al. Peritoneal dialysis-related infections
recommendations: 2005 update. Perit Dial Int 2005; 25: 107–131.
6. Amici G, Virga G, Ronco C. Automated peritoneal dialysis: when and how
to do it. Perit Dial Int 1999; 19: S115–S120.
7. Amici G, Grandesso S, Mottola A et al. Fungal peritonitis in peritoneal
dialysis: critical review of six cases. Adv Perit Dial 1994; 10: 169–173.
8. Cheng IK, Fang GX, Chan TM et al. Fungal peritonitis complicating
peritoneal dialysis: report of 27 cases and review of treatment. Q J Med
1989; 71: 407–416.
9. Saran R, Goel S, Khanna R. Fungal peritonitis in continuous ambulatory
peritoneal dialysis. Int J Artif Organs 1996; 19: 441–445.
10. Tapson JS, Mansy H, Freeman R et al. The high morbidity of CAPD fungal
peritonitis – description of 10 cases and review of treatment strategies.
Q J Med 1986; 61: 1047–1053.
11. Eisenberg ES, Leviton I, Soeiro R. Fungal peritonitis in patients receiving
peritoneal dialysis: experience with 11 patients and review of the
literature. Rev Infect Dis 1986; 8: 309–321.
12. Kerr CM, Perfect JR, Craven PC et al. Fungal peritonitis in patients on
continuous ambulatory peritoneal dialysis. Ann Intern Med 1983; 99:
334–336.
13. Rault R. Candida peritonitis complicating chronic peritoneal dialysis: a
report of five cases and review of the literature. Am J Kidney Dis 1983; 2:
544–547.
14. Wang AY, Yu AW, Li PK et al. Factors predicting outcome of fungal
peritonitis in peritoneal dialysis: analysis of a 9-year experience of fungal
peritonitis in a single center. Am J Kidney Dis 2000; 36: 1183–1192.
15. Goldie SJ, Kiernan-Tridle L, Torres C et al. Fungal peritonitis in a large
chronic peritoneal dialysis population: a report of 55 episodes.
Am J Kidney Dis 1996; 28: 86–91.
16. Ram R, Swarnalatha G, Neela P et al. Fungal peritonitis in patients on
continuous ambulatory peritoneal dialysis: a single-centre experience in
India. Nephron Clin Pract 2008; 110: c207–c212.
17. Das R, Vaux E, Barker L et al. Fungal peritonitis complicating peritoneal
dialysis: report of 18 cases and analysis of outcomes. Adv Perit Dial 2006;
22: 55–59.
18. Prasad KN, Prasad N, Gupta A et al. Fungal peritonitis in patients on
continuous ambulatory peritoneal dialysis: a single centre Indian
experience. J Infect 2004; 48: 96–101.
19. Lo WK, Chan CY, Cheng SW et al. A prospective randomized control study
of oral nystatin prophylaxis for Candida peritonitis complicating
continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1996; 28:
549–552.
20. Strippoli GF, Tong A, Johnson D et al. Antimicrobial agents for preventing
peritonitis in peritoneal dialysis patients. Cochrane Database Syst Rev
2004: CD004679.
21. Lim WH, Johnson DW, McDonald SP. Higher rate and earlier peritonitis in
Aboriginal patients compared to non-Aboriginal patients with end-stage
renal failure maintained on peritoneal dialysis in Australia: analysis of
ANZDATA. Nephrology (Carlton) 2005; 10: 192–197.
22. Greaves I, Kane K, Richards NT et al. Pigeons and peritonitis? Nephrol Dial
Transplant 1992; 7: 967–969.
23. Yuen KY, Seto WH, Ching TY et al. An outbreak of Candida tropicalis
peritonitis in patients on intermittent peritoneal dialysis. J Hosp Infect
1992; 22: 65–72.
24. Cass A, Cunningham J, Snelling P et al. End-stage renal disease in
indigenous Australians: a disease of disadvantage. Ethn Dis 2002; 12:
373–378.
25. Cass A, Gillin AG, Horvath JS. End-stage renal disease in aboriginals in
New South Wales: a very different picture to the Northern Territory.
Med J Aust 1999; 171: 407–410.
26. McCullagh P, Nelder JA. Generalised linear models. Chapman and Hall:
London, 1989.
628 Kidney International (2009) 76, 622–628
or ig ina l a r t i c l e R Miles et al.: Fungal peritonitis
